Recently, the animal health company
Zoetis (ZTS) has been on a significant investment radar. A variety of wealth and investment advisory firms have engaged in buying, selling, and holding ZTS stock, as seen through actions from Gratus Wealth Advisors, IMA Advisory Services and others. However, some investors such as Aristotle Atlantic and Y Intercept have offloaded substantial ZTS due to competition worries. Despite these selling activities, Zoetis still managed to outperform the general market, drawing praises as a
strong growth stock. There are also bullish Wall Street views favoring the company. Prominent financial players like Peterson Wealth Services, Universal Beteiligungs and William Allan Corp continue to acquire Zoetis shares, signaling their confidence. Meanwhile, Argus trimmed the Zoetis' price target to $190 but maintains a constructive view. However, the company suffered a more significant decline compared with the overall market, but it managed to bounce back and has been prosperous ever since. Regrettably, Leerink Partnrs downgraded Zoetis to a 'Hold' rating. The company remains a potential candidate for a unique dividend play in the Pharma space until 2025.
Zoetis ZTS News Analytics from Mon, 30 Dec 2024 08:00:00 GMT to Sat, 26 Jul 2025 20:13:42 GMT -
Rating 6
- Innovation 3
- Information 9
- Rumor -2
